Jiahui, Fosun Kite to collaborate on CAR-T program
Print Edition
Nearly six months after the approval of the first CAR-T cell therapy — axicabtagene ciloleucel injection — in China, the CAR-T Program Strategic Cooperation Agreement was officially signed between Shanghai Jiahui International Hospital and Fosun Kite on December 7.
The two sides will collaborate on clinical research, academic exchanges, treatment processes as well as innovative payment models. With the strong support of Fosun Kite, Shanghai Jiahui International Cancer Center has thus become part of the first batch of medical institutions in China to provide patients with CAR-T (chimeric antigen receptor T-cell) therapy service.
“Together we have built a standardized service process for CAR-T therapy at Jiahui International Cancer Center, and a professional CAR-T service team will be formed, comprising Jiahui doctors, nurses and pharmacists, to provide patients with high-quality CAR-T therapy services,” said Feng Ge, CEO of Jiahui Health, which operates Shanghai Jiahui International Hospital.
“We will continue to move forward and innovate while promoting international standard immunotherapy, and we will explore and develop clinical research projects on CAR-T cell immunotherapy together with our international and domestic partners for the benefit of more cancer patients.”
Hai Huang, CEO of Fosun Kite, said at the ceremony that “As a revolutionary therapy in cancer treatment, CAR-T cell therapy provides hope and opportunity for deep sustained remission and long-term survival with a single infusion.”
“Unlike the marketing model of traditional pharmaceutical products, Fosun Kite’s cooperation with hematology departments of general hospitals or cancer hospitals across China focuses on providing services for them. This includes ensuring high-quality standardized treatment for patients by providing relevant departments and doctors with training, enabling them to achieve standardized treatment certifications consistent with global standards.”
CAR-T is a new type of precision therapy for the treatment of tumors. Axicabtagene ciloleucel injection, the first CAR-T medicine approved in China, is used to treat adult patients who have relapsed or refractory large B-cell lymphoma after previous second-line or failed after second lines of treatment.
The news of its release in China has attracted unprecedented attention. However, few people understand the complexity and difficulty of the CAR-T therapy process in clinical application.
Professor Lily Zhou, project leader of the CAR-T program as well as deputy director of Clinical Operations of Jiahui International Cancer Center, who specializes in hematological tumor treatment, explained, “CAR-T is a kind of individualized cellular immunotherapy, where the timing of treatment has to be judged according to the individual patient’s condition, and it achieves the purpose of activating autoimmunity and killing tumor cells by collecting cells after comprehensive treatment and then expands and transfuses them back after in vitro modification.
“CAR-T therapy has extremely high professional requirements for medical institutions in different aspects such as patient screening, pre-treatment, management of side effects, and whole journey because of its highly individualized character.”
Zhou continued: “Shanghai Jiahui International Hospital has always attached great importance to patient safety throughout the treatment process. We have established a multidisciplinary CAR-T rapid response team, including the directors of the cancer center, neurology, cardiology, respiratory medicine, emergency medicine, clinical laboratory, pharmacy and other departments, and have repeatedly conducted multiple rounds of clinical training and scenario simulations beforehand.”
All members of the CAR-T team are assessed and evaluated to ensure the comprehensive management of CAR-T therapy, she revealed, adding that Jiahui International Cancer Center is equipped with a dedicated CAR-T ward to fully ensure patient monitoring needs in terms of hardware and software.
In addition to process control and standardized joint development, Jiahui, along with Fosun Kite, will conduct active exploration and support patient assistance around the innovative payment model of CAR-T to promote the accessibility of CAR-T pharmaceutical therapy and further reduce the burden on patients.
Jiahui and Fosun Kite will also jointly build an international CAR-T therapy platform and establish a CAR-T cell therapy center at Jiahui International Cancer Center. Furthermore, they will continue to develop clinical research and actively carry out international and domestic academic activities to foster research of CAR-T therapies in China, enabling more patients to benefit from it.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
